Zealand Pharma A/S
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adam Sinding Steensberg
- Full Time Employees
- 544
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Sydmarken 11 Copenhagen Denmark 2860
- IPO Date
- Feb 25, 2013
- CIK
- 0002068427
- Website
- zealandpharma.com
- Similar Companies
- Business
- Zealand Pharma A/S is a Denmark-based biotechnology company specializing in the discovery, design, development, and commercialization of innovative peptide-based medicines primarily targeting metabolic and gastrointestinal diseases, obesity, and rare diseases with unmet medical needs. The company’s core products include Dasiglucagon, a glucagon analog formulation used in single-use syringes and autoinjectors for severe hypoglycemia treatment and in bi-hormone artificial pancreas systems; Glepaglutide, a long-acting GLP-2 analog in Phase III clinical trials for short bowel syndrome; and other peptide drug candidates focused on diabetes, obesity, and rare diseases. Zealand Pharma operates in Denmark and the USA and maintains development and commercial partnerships with several pharmaceutical companies, including a notable collaboration with Boehringer Ingelheim. Recent major developments include a transformational global collaboration and licensing agreement with Roche to co-develop and co-commercialize Petrelintide, Zealand Pharma’s proprietary amylin analog aimed at weight management and related indications. This agreement, signed in March 2025, entails up to USD 5.3 billion in potential milestones and upfront payments exceeding USD 1.6 billion, underscoring a significant strategic expansion into obesity therapeutics. Additionally, Zealand Pharma completed an upsized equity offering in mid-2024, raising approximately USD 1 billion to advance its proprietary obesity pipeline in Phase 2b and beyond, along with associated manufacturing and clinical development activities. The company also partnered with Benchling in 2024 to enhance its R&D capabilities through integrated scientific data management and collaboration tools. Incorporated in 1997 and headquartered in Søborg, Denmark, Zealand Pharma employs over 420 personnel and maintains a clinical pipeline comprising multiple peptide-based candidates across phases I to III. The company focuses on delivering innovative peptide therapeutics for patients with serious metabolic and rare diseases and continues to pursue strategic partnerships to maximize both development and commercial potential globally. Zealand Pharma balances proprietary research with collaborations, positioning itself as a key player in the biotechnology sector centered on peptide medicines.
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Drugmakers race to find a place in the next wave of obesity drugs
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Is Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now?
Zealand Pharma A/S (ZLDPY) Q1 2026 Earnings Call Transcript
Zealand Pharma A/S (ZLDPF) Reports Q1 Loss, Lags Revenue Estimates
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript
Zealand Pharma A/S (ZLDPF) Q4 2025 Earnings Call Transcript
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 6.8% Jump Turn into More Strength?
Zealand Pharma A/S (ZLDPF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zealand Pharma A/S (ZLDPF) Analyst/Investor Day Transcript
Zealand Pharma to accelerate drug development for obesity, metabolic disease